Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

h the use of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The m
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Somewhere ... addressing hearing health was forgotten. But Audicus , ... to hear better this new year. Hearing ... facing the aging population, though it is often unaddressed. ... in four has a hearing aid, mainly due to ...
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Cylene Pharmaceuticals announced today that it has initiated a ... kinase inhibitor, CX-4945, in patients with advanced solid tumors, ... the oral dose escalating trial are determination of safety, ... the appropriate dose for Phase II trials. In addition, ...
... resonance imaging (MRI) is a growing technology providing an ... evaluation of back pain according to an article in ... American Academy of Orthopaedic Surgeons ( http://www.jaaos.org/ ). ... additional technical developments will allow MRI to provide even ...
Cached Medicine Technology:Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3
(Date:12/21/2014)... 2014 Recently, BambooFlooringChina.com, a famous bamboo ... bamboo flooring collection , and launched a bamboo flooring ... is valid until Jan. 30, 2015. , According to ... the hardest bamboo flooring available today; it has a ... traditional teak hardwoods. Strand woven bamboo is made by ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Khanna Vision ... a guest at the Aspen Helicopters holiday event for ... a Santa with sleigh, flown by an aspen helicopter ... invisible; only Santa with sleigh was visible.(please see accompanying ... and night. Dr.Khanna has helped many pilots with Pi ...
(Date:12/21/2014)... December 21, 2014 Hundreds of ... liability claims involving a class of Type 2 ... move forward in a federal multidistrict litigation now ... California, Bernstein Liebhard LLP reports. According to an ... a data cut-off date of February 27, 2014 ...
(Date:12/21/2014)... York, NY (PRWEB) December 21, 2014 ... nearing 1,400 in a consolidated litigation underway in New ... documents, a total of 1,375 claims involving the birth ... Superior Court. These lawsuits were filed by women who ... to have led to uterine perforations and other complications ...
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3
... Chairman of the Board of Directors for Intelligent Hospital ... Erik Hansen as Chief Executive Officer, effective May 11, ... McGarry held the dual positions of Chairman of the ... from a research and development culture into a highly ...
... Joe and Sue Paterno in New York City ... CHESTER, Pa., May 8 The Charcot-Marie-Tooth Association,s second annual ... Sue Paterno for a lifetime of achievement raised a record ... New York City on April 29. Proceeds earned from event ...
... of early stage breast cancer patients has shown that a ... just as accurate as current techniques, but faster, more specific ... molecular biology to enter the operating room for lymph node ... surgery at the UC San Diego School of Medicine and ...
... Model Collaboration and Mother,s Day Challenge Grant Demonstrate ... Health NeedsNEW YORK, and FRANKLIN LAKES, N.J., May ... (Becton, Dickinson and Company), a leading global medical ... United Nations Children,s Fund (UNICEF) campaign to vaccinate ...
... 8 Prematics Inc. has selected S. Michael Ross, ... officer and senior vice president of business development. Dr. ... health care enterprise clients, helping them leverage Prematics, innovative ... and members at the point of care.(Logo: ...
... Society should consider ways to mitigate the effects, experts say, ... can lead not just to financial hardships but to health ... heart attack and stroke, new research has found. , "In ... who conducted the research as a Robert Wood Johnson Foundation ...
Cached Medicine News:Health News:Charcot-Marie-Tooth Association's 'Honor a Star. Be a Star.' Gala Generates Over $350,000 for CMT Research 2Health News:New technique may help detect potential breast cancer spread 2Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 2Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 3Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 4Health News:Prematics Names S. Michael Ross Chief Medical Officer and Senior Vice President of Business Development 2Health News:Prematics Names S. Michael Ross Chief Medical Officer and Senior Vice President of Business Development 3Health News:After Job Loss, People Report More Health Issues 2
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
... an expanded database containing over 330 ... cards, VITEK 2 Compact offers enhanced ... of time (2 to 14 hours), ... microorganisms that contaminate production areas and ...
... is a comprehensive hemodynamic monitoring and ... lab. Patient demographics, clinical hemodynamic ... procedural information all flow seamlessly into ... repetitive data entry. Both ...
... generation product is a patient monitoring system ... parameters, sensed at the tissue level, reflecting ... tissue by low power light and detects ... tissue. The light is guided to the ...
Medicine Products: